LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitor...
| Autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:277630 |
| Acceso en línea: | https://ddd.uab.cat/record/277630 https://dx.doi.org/urn:doi:10.3389/fimmu.2023.1066393 |
| Access Level: | acceso abierto |
| Palabra clave: | LAG3: lymphocyte activation gene 3 Graft-versus-host disease Allogeneic transplant Immune response Checkpoint molecules |
| Sumario: | The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule. To determine its role in the alloHSCT setting, we analyzed 797 patients transplanted from HLA-identical sibling donors. The LAG3 rs870849 C. |
|---|